Fig. 1: SLC5A3 upregulation in NSCLC.
From: The sodium/myo-inositol co-transporter SLC5A3 promotes non-small cell lung cancer cell growth
SLC5A3 mRNA expression in NSCLC tumor tissues (“Tumor”, n = 1037) and normal lung tissues (“Normal”, n = 106) from TCGA cohorts was presented (A). SLC5A3 mRNA expression in NSCLC tumor tissues (“Tumor”, n = 106) and paired adjacent normal lung tissues (“Normal”, n = 106) from TCGA cohorts was shown (B). mRNA and protein expression of SLC5A3 in local NSCLC tumor tissues (“T”, n = 13) and paired adjacent normal lung tissues (“N”, n = 13) was tested by qRT-PCR (C) and Western blotting (D and E) assays; The representative tissue IHC (immunohistochemistry) results confirmed SLC5A3 upregulation in NSCLC tumor slides of two representative patients (Patient #1 and Patient #2) (F). SLC5A3 mRNA and listed proteins in the described NSCLC cells and epithelial cells were tested (G and H). The relative myo-inositol (MI) contents were measured as well (I). Data were presented as mean ± standard deviation (SD). *P < 0.05 versus “N” tissues (C and E) or “pEpi” cells (G–I). Scale bar = 100 μm (F).
